RALEIGH — Sprout Pharmaceuticals has sold options and securities in a debt round to raise more than $8.1 million, according to a regulatory filing. Sprout makes the FDA-approved female sexual disfunction drug Addyi.
Raleigh-based Sprout says evidence in tests“demonstrates significant improvements in female sexual disfunction for arousal, desire, lubrication, satisfaction and orgasm,” via use of Addyl.
The FDA had some problems with a press release the company issued, worrying that it could be confusing.
The Securities and Exchange Commission filing notes that 59 investors participate in the raise.
According to earlier filings, the company raised $15.9 million in 2019, and $4.5 million in 2018, both equity rounds.
FDA, Sprout Pharmaceuticals tangle again over ‘female Viagra’ drug restrictions
